Valuation: Precision BioSciences, Inc.

Market Cap 211M 185M 170M 158M 300M 20.1B 304M 2.04B 791M 9.88B 792M 775M 34.04B P/E 2026 *
-2.96x
P/E 2027 * -3.18x
Enterprise Value 211M 185M 170M 158M 300M 20.1B 304M 2.04B 791M 9.88B 792M 775M 34.04B EV / Sales 2026 *
11.2x
EV / Sales 2027 * 16.9x
Free-Float
93.46%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision BioSciences, Inc.

1 day+3.81%
1 week+12.21%
Current month+4.07%
1 month+25.85%
3 months+40.55%
6 months+100.49%
Current year+96.63%
1 week 7.55
Extreme 7.55
8.34
1 month 6.03
Extreme 6.03
8.34
Current year 3.53
Extreme 3.53
8.59
1 year 3.53
Extreme 3.53
8.82
3 years 3.53
Extreme 3.53
21.9
5 years 3.53
Extreme 3.53
431.4
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2006-01-25
Chief Executive Officer 48 2021-10-14
Director of Finance/CFO 59 2020-12-31
Director TitleAgeSince
Chairman 68 2020-10-31
Director/Board Member 65 2020-03-09
Director/Board Member 69 2022-05-30
Date Insider Type Main position Quantity % Market Cap.
06-02Free

Director

20,979 0.0872%
06-02Free

Director

20,979 0.0872%
06-02Free

Director

20,979 0.0872%
Change 5-day change 1-year change 3-year change Capi.($)
+3.81%+12.21%+88.48%-47.59% 211M
+1.70%+7.41%+2.50%+8.18% 49.92B
+0.92%+3.93%+399.71%+604.02% 40.23B
+1.89%+8.32%+26.06%-6.27% 34.55B
+2.38%+6.35%+21.25%+55.45% 33.09B
+3.96%+10.67%+8.30%+37.95% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+135.37% 15.92B
+0.32%+0.58%+14.00%+19.09% 13.86B
+3.30%+0.76%+90.23%+93.88% 13.52B
Average +2.34%+7.36%+80.44%+100.01% 24.59B
Weighted average by Cap. +2.07%+6.55%+90.20%+135.70%

Financials

2026 *2027 *
Net sales 18.81M 16.44M 15.11M 14.09M 26.72M 1.79B 27.12M 181M 70.52M 880M 70.6M 69.09M 3.03B 12.52M 10.94M 10.06M 9.38M 17.78M 1.19B 18.05M 121M 46.94M 586M 47M 45.99M 2.02B
Net income -77.69M -67.92M -62.41M -58.18M -110M -7.4B -112M -749M -291M -3.64B -292M -285M -12.53B -86.26M -75.41M -69.3M -64.59M -123M -8.21B -124M -832M -323M -4.04B -324M -317M -13.91B
Net Debt - -
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Employees
66
Date Price Change Volume
26-07-02 US$8.180 +3.81% 600,930
26-07-01 US$7.880 +0.25% 446,050
26-06-30 US$7.860 -0.76% 484,325
26-06-29 US$7.920 +8.64% 774,620
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.180USD
Average target price
29.60USD
Spread / Average Target
+261.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DTIL Stock